linjc16/ctgov huggingface dataset:
Efficacy and Saffety of Oral Immunotherapy to Pistachio

Study Overview
=================
Brief Summary
-----------------
The objectives of this study are (i) to evaluate the efficacy of oral immunotherapy to pistachio by evaluating the daily oral tolerance of 2g pistachio, by evaluating the long-term tolerance of 15g pistachio (sustained unresponsiveness) and by decreasing pistachio-specific IgE, (ii) evaluating the efficacy of pistachio immunotherapy on cashew tolerance, (iii) and to evaluate the safety of pistachio immunotherapy.

Official Title
-----------------
Efficacy of Oral Immunotherapy to Pistachio in Children on the Oral Tolerance to Pistachio and Cashew Nuts

Conditions
-----------------
Food Allergy, Allergy

Intervention / Treatment
-----------------
* Other: Food allergy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients under 18 years of age with a proven allergy to pistachio and followed in the pediatric allergology unit of the Nancy University Hospital. Patients who have received oral immunotherapy to pistachio for at least 18 months at 31/12/2022 Exclusion Criteria: Patients who have received oral immunotherapy to pistachio for less than 18 months. Patients lost to follow-up for more than 2 years or last consultation dating from 2020 or earlier

Ages Eligible for Study
-----------------
Minimum Age: 1 Year
Maximum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: Food allergy|Oral immunotherapy to pistachio|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Absence of moderate to severe allergic reactions | with daily intake of 2g of pistachio | during the 6 months of maintenance | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Frequency and severity of allergic reactions |  | during the dose escalation phase and during the maintenance phase (first 6 months, 1st year, 2nd year, 3rd year) | 
| Decrease in specific IgE and increase of IGg4 to pistachio |  | during the dose escalation phase and during the maintenance phase (first 6 months, 1st year, 2nd year, 3rd year) | 
| Tolerance of 1, 2, 4, 8g in isolated doses and 15 g in total cumulative dose of pistachio | during an oral pistachio challenge test | 3 months after stopping daily consumption of 2g pistachio | 
| Tolerance of 1, 2, 4, 8g in isolated doses and 15 g in total cumulative dose of cashew nut | during an oral cashew nut challenge test | 3 months after stopping daily consumption of 2g pistachio | 
| Reactogenic or tolerogenic threshold of cashew nuts |  | during the dose escalation phase and during the maintenance phase (first 6 months, 1st year, 2nd year, 3rd year) |
Correlation of Disease Management and Quality of Life in Patients With Chronic Heart Failure and Their Family Caregivers

Study Overview
=================
Brief Summary
-----------------
This study intends to investigate the current status of disease management and quality of life of patients with chronic heart failure and their family caregivers, explore the relationship between the two sides of disease management and quality of life, help nurses identify the influencing factors of quality of life of patients with chronic heart failure and their family caregivers, and carry out family-centered care in the future. This study intends to investigate the current status of disease management and quality of life of patients with chronic heart failure and their family caregivers, explore the relationship between disease management and quality of life of both sides, and help nurses identify the influencing factors affecting the quality of life of patients with chronic heart failure and their family caregivers, so as to carry out family-centered care in the future. To provide theoretical basis for improving the quality of life of both parties.

Official Title
-----------------
Correlation of Disease Management and Quality of Life in Patients With Chronic Heart Failure and Their Family Caregivers

Conditions
-----------------
Chronic Heart Failure

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Meet the diagnostic criteria of Chinese Guidelines for the diagnosis and treatment of heart failure the duration of chronic heart failure was ≥3 months; have certain reading, comprehension and expression ability, and can complete the questionnaire independently or with the guidance of the researcher; Informed and agreed to participate in the investigation Exclusion Criteria: In the acute stage of the disease, such as acute heart failure attack or complicated with severe pulmonary infection, liver and kidney function damage, etc.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 100 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| the quality of life questionnaire | Quality of life refers to the subjective feelings of individuals about their own goals, expectations, standards, and life situations related to the things they care about in different cultures and value systems | 10 months |
Clinical Relevance of the Salvage Treatment for Colorectal Neuroendocrine Tumors

Study Overview
=================
Brief Summary
-----------------
we evaluated all related clinical and pathologic data of rectal NET cases, including the resection margin status, NET grading, and lymphovascular invasion status. Finally, the present study was aimed at (1) determining the risk factors for LN and distant metastases in colorectal NETs (2) clarifying the clinical significance of the salvage treatment for colorectal neuroendocrine tumors following initial endoscopic resection with positive resection margin status and (3) compare different salvage treatment of this uncommon disease through conducting a large, multi-center cohort study.

Official Title
-----------------
Clinical Relevance of the Salvage Treatment for Colorectal Neuroendocrine Tumors Based on the Pathological Evaluation Following Initial Endoscopic Resection: A Multi-center Study

Conditions
-----------------
Rectal Neoplasms, Neuroendocrine Tumors

Intervention / Treatment
-----------------
* Procedure: salvage treatment


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: within the age range of 18 to 65 years, diagnosed with rectal neuroendocrine tumors. Furthermore, patients were required to have a palpable tumor as determined by digital rectal examination or accessible through proctoscopy, with the distal border situated within 12 cm from the anal verge. Exclusion Criteria: (1) muscularis propria invasion or NET grading = 3, (2)regional LN or distant organs metastasis at the time of diagnosis, (3) incomplete follow-up information, (4) the patient had multiple primary tumors, (5) patients with surgical excision or inappropriate methods such as forceps removal, and (6) the patient had a history of malignant tumors.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| salvage treatment group<br>patients with salvage treatment after endoscopic resection were diagnosed as having positive resection margin status | Procedure: salvage treatment<br>* salvage radical surgery or endoscopic resection<br>|
| without salvage treatment group<br>patients without salvage treatment after endoscopic resection were diagnosed as having positive resection margin status | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| DFS | disease free survival | 5 year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
endoscopic resection
Comprehensive Assessment on Diagnostic and Prognostic Performance of Coronary Physiological Indices

Study Overview
=================
Brief Summary
-----------------
The objective of the Zhongshan Hospital CONCORDE Registry is to evaluate utility, diagnostic value, and clinical outcomes of coronary physiological indices in an all-comers population of patients with suspected coronary artery disease referred to invasive coronary angiography in order to further inform patients and health care providers about which technologies are most effective and efficient in the diagnosis and management of coronary artery diseases.

Detailed Description
-----------------
CONCORDE registry offers a comprehensive pressure and/or flow measurements, as well as angiography-derived functional assessment of coronary. Patient treatment was at the operator's discretion at the time of the invasive procedure. A standardized data collection sheet was used and data were extracted from electrical medical history according to standardized definition of patient's baseline characteristics, clinical outcomes, and physiologic data.

Official Title
-----------------
Comprehensive Assessment on Diagnostic and Prognostic Performance of Coronary Physiological Indices in Patients Referred to Angiography

Conditions
-----------------
Coronary Artery Disease

Intervention / Treatment
-----------------
* Other: coronary physiological indices


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: suspected coronary artery disease referred to invasive coronary angiography Exclusion Criteria: hemodynamic instability

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 99 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| All patients<br>All patients referred to angiography and undergo assessment with coronary pressure sensor | Other: coronary physiological indices<br>* Resting distal coronary to aortic pressure ratio, Fractional flow reserve, Resting full-cycle ratio, Coronary Flow Reserve, Microvascular resistance<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Major adverse cardiac events (MACE) | Cumulative incidence of a composite of any death, any myocardial infarction, or any ischemia-driven revascularization | 5 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Target vessel failure (TVF) | Cumulative incidence of a composite of cardiac death, target-vessel related myocardial infarction, or target-vessel revascularization | 5 years | 
| Individual components of MACE and TVF | Cumulative incidence of the individual components of MACE and TVF | 5 years |
Effect Of High Power Laser On Radiotherapy Induced Trismus.

Study Overview
=================
Brief Summary
-----------------
this study Randomized controlled study will be conducted to study (the effect of high power laser therapy on radiotherapy induced trismus in head and neck cancer patients). the study group will receive high power laser therapy in combination with conventional tempromandibular joint exercises. the control group will receive conventional tempromandibular joint exercises.

Official Title
-----------------
Effect Of High Power Laser Therapy On Radiotherapy Induced Trismus In Head And Neck Cancer Patients

Conditions
-----------------
Trismus

Intervention / Treatment
-----------------
* Device: high power laser therapy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: head and neck cancer patients who complain of decreased mouth opening and received or receiving radiotherapy. patients who complain from pain and inflammation in the tempromandibular joint due to radiotherapy. radiotherapy should be above 40 GY. patient ages between 20 to 65 years old. Exclusion Criteria: patients with poor general health. patients with difficulties in filling questionnaire. patients who are complaining of other tempomandibular problems other than trismus such as (disc discplacement and trumatic mandibular fractures.

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: experimental group<br>study group receive high power laser therapy in combination with conventional tempromandibular joint exercises. | Device: high power laser therapy<br>* m6 laser therapy of ASA company with multilocked wave system and synchronized emission wave lengths 808 and 905 wave lengths<br>* Other names: conventional tempromandibular joint exercises;|
| Active Comparator: control group<br>control group receive traditional tempromadibular joint exercises. | Device: high power laser therapy<br>* m6 laser therapy of ASA company with multilocked wave system and synchronized emission wave lengths 808 and 905 wave lengths<br>* Other names: conventional tempromandibular joint exercises;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| pain level | visual analogue scale | one month (4 weeks) | 
| mouth opening | verneir caliper | one month (4 weeks) | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| quality of life improvement | Washington quality of life questionnaire | one month (4 weeks) |
CERAMENT G Device Registry

Study Overview
=================
Brief Summary
-----------------
This is an Observational Device Registry Study of CERAMENT|G in normal use in accordance with the IFU. It will run for a period of three years from enrolment of the first patient into the Study at each Site, before being subject to review. A Device Registry is a form of observational study that concerns the performance of a device in normal use. It is intended to collect data that is reflective of 'real world' device performance.

Official Title
-----------------
CERAMENT G Device Registry

Conditions
-----------------
Chronic Osteomyelitis, Fracture Related Infection, Diabetic Foot Osteomyelitis

Intervention / Treatment
-----------------
* Device: CERAMENT G


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 18 years and over (on the day of surgery) receive CERAMENT|G as a component of their treatment at a participating, contracted centre or healthcare provider, in accordance with the IFU for the implanted product In receipt of patient information leaflet and have signed appropriately designed informed consent form. Exclusion Criteria: Any exclusion criteria as per IFU for CERAMENT|G Any off-label use

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Device: CERAMENT G|Primary mode of action is to be a resorbable ceramic bone graft substitute intended to fill gaps and voids in the skeleton system to promote bone healing. CERAMENT ™|G provides a void/gap filler that during the surgical procedure can augment hardware and bone alignments. Secondary mode of action is to prevent colonization of Gentamicin sensitive microorganisms in order to protect bone healing.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Primary Outcomes | • Device safety - any unexpected device performance, complaints, adverse events, adverse device effects, SAEs throughout study period. | 12 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Secondary Outcome | Bone healing at final follow-up | 12 months | 
| Secondary Outcome | Pain and functional assessment at whatever follow-up times are usual for the specific clinical site, for example 6 & 12 months, if normally conducted | 6 and 12 months | 
| Secondary Outcome | (Recurrence of) infection/revision surgery | 12 months |
Incidence of the Out- and in Hospital Cardiac Arrest at a Tertiary Hospital in Germany

Study Overview
=================
Brief Summary
-----------------
Incidence of the background information, incidence and special characteristics of out- and in-hospital cardiac arrest at a tertiary hospital in Germany.

Detailed Description
-----------------
To evaluate background information for planning a eCPR Program at a tertiary hospital, the investigators planned a prospective study of every out- and in-hospital cardiac arrest.

Official Title
-----------------
Incidence and Special Informations From Patients of the Out- and in Hospital Cardiac Arrest at a Tertiary Hospital in Germany

Conditions
-----------------
Resuscitation

Intervention / Treatment
-----------------
* Other: Time to Decision for eCPR


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All patients with a cardiac arrest Exclusion Criteria: not complete fill out evaluation forms
Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Out-of-hospital cardiac arrest<br>Patient characteristics; Rescue time intervals; Time to eCPR Decision during high quality CPR; | Other: Time to Decision for eCPR<br>* We evaluate during high quality CPR the time for decision for eCPR<br>* Other names: Pros eCPR;|
| In-hospital cardiac arrest<br>Patient characteristics; Emergency team time intervals; Time to eCPR Decision during high quality CPR; | Other: Time to Decision for eCPR<br>* We evaluate during high quality CPR the time for decision for eCPR<br>* Other names: Pros eCPR;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Time to eCPR Decision during high quality CPR | After established high quality CPR, we evaluate the time of decision for eCPR | < 10 Minutes | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Patient characteristics | Age, BMI, comorbidity, contraindications for ECMO | < 10 Minutes | 
| Rescue/Emergency team time intervals | Time to Achievement at the patient; Time for transport | < 60 Minutes |
A Study of Chronic Hepatitis C Patients Treated With SOF/VEL/VOX

Study Overview
=================
Brief Summary
-----------------
This is a retrospective, non-interventional study. Investigators from infectious diseases and gastroenterology departments will participate this study. Patients data will be collected from hospital medical records.

Detailed Description
-----------------
Pangenotypic Sofosbuvir/Velpatasvir/Voxilaprevir for 8-12 weeks has been shown highly effective, safe, and well-tolerated in treating patients with chronic HCV infection in clinical trial settings, however, there are no real-world setting data are available.This is the first opportunity from all over the world to demonstrate SOF/VEL/VOXs efficacy and safety in Real World setting especially for the naive patients. SOF/VEL/VOX is often positioned in retreatment by international guidelines. Previously the reimbursement guideline in Turkey did not allow patients to be re-treated after the failure of DAA treatments. With current guideline Vosevi is approved as the only option for failures of DAA treatments. In the past years in Turkey, SOF+RBV in GT2, SOF+PEF+RBV in GT3, LDV/SOF in GT1.4-6 patients and Viekirax/Exviera in GT1,4 patients have been used and unfortunately, some patients did not benefit from these suboptimal treatments. The efficacy and safety of SOF/VEL/VOX in patients who have experienced treatment failure in real life will be another objective of the research. This research will support Efficacy and safety of 8-week Pangenotypic SOF/VEL/VOX for treatment naive non-cirrhotics Efficacy and safety of 12-week Pangenotypic SOF/VEL/VOX for treatment naive compensate cirrhotics Efficacy and safety of 12-week Pangenotypic SOF/VEL/VOX for retreatment of NS5A or NS3A4 and non-NS5A treatment-experienced patients (incl. noncirrhotics and cirrhotics)

Official Title
-----------------
A Retrospective Study of Chronic Hepatitis C Patients Treated With SOF/VEL/VOX: Real Life Study

Conditions
-----------------
Hepatitis C

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients diagnosed as chronic hepatitis C and aged 18 and older Patients received SOF/VEL/VOX treatment Exclusion Criteria: Decompensated cirrhotic HCV patients Having HCC eGFR<30 ml/min

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Sustained Virology Response 12 | Rate of the patients with undetectabled HCVRNA after 12 weeks of the completion of SOF/VEL/VOX treatment | From start date of treatment to 12 weeks after the completion of treatment | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Hepatitis C, VOSEVI
Prospective Carotid Artery Stenosis Trial

Study Overview
=================
Brief Summary
-----------------
Researchers are collecting information and blood from subjects undergoing carotid artery interventions.

Official Title
-----------------
Prospective Carotid Artery Stenosis Trial

Conditions
-----------------
Patients With Any Degree of Carotid Artery Stenosis and Vulnerable Features in the Carotid Artery Plaque

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All subjects undergoing carotid artery intervention that presents to our clinic Exclusion Criteria: None

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Biospecimen Acquisition | Number of biospecimens collected | 1 month |